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Abstract
Background: Gene set testing, or pathway analysis, is a bioinformatics technique that performs statistical testing on
biologically meaningful sets of genomic variables. Although originally developed for supervised analyses, i.e., to test
the association between gene sets and an outcome variable, gene set testing also has important unsupervised
applications, e.g., p-value weighting. For unsupervised testing, however, few effective gene set testing methods are
available with support especially poor for several biologically relevant use cases.
Results: In this paper, we describe two new unsupervised gene set testing methods based on randommatrix theory,
the Marc˘enko-Pastur Distribution Test (MPDT) and the Tracy-Widom Test (TWT), that support both self-contained and
competitive null hypotheses. For the self-contained case, we contrast our proposed tests with the classic multivariate
test based on a modified likelihood ratio criterion. For the competitive case, we compare the new tests against a
competitive version of the classic test and our recently developed Spectral Gene Set Enrichment (SGSE) method.
Evaluation of the TWT and MPDT methods is based on both simulation studies and a weighted p-value analysis of two
real gene expression data sets using gene sets drawn from MSigDB collections.
Conclusions: The MPDT and TWT methods are novel and effective tools for unsupervised gene set analysis with
superior statistical performance relative to existing techniques and the ability to generate biologically important
results on real genomic data sets.
Keywords: Gene set testing, Pathway analysis, Randommatrix theory, Tracy-Widom, Marc˘enko-Pastur
Background
Gene set testing, or pathway analysis, is a powerful and
extensively employed approach for analyzing the output
from large scale assaying techniques for nucleic acids
and nucleic acid products, such as microarrays and high-
throughput sequencing [1, 2]. By focusing the analysis on
the association between a smaller number of functional
gene sets and a specific clinical outcome, gene set test-
ing can substantially improve statistical power, biological
interpretation and replication relative to an analysis based
on individual genomic variables [1, 3–5]. Given these
advantages, researchers have invested significant effort in
the last 10 to 15 years creating large gene set collections
[6–8] and developing effective gene set testing methods
[4, 9–12].
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Gene set testing was originally developed for use in
a supervised context, i.e., to quantify the association
between a set of genomic variables, or genes, and a clin-
ical outcome or phenotype. Typically, this is carried out
via a two-stage process in which the association is first
measured between each gene in the set and the pheno-
type, often using a simple linear regression model. The
test statistics for all genes in the set are then combined
into a gene set test statistic and significance is computed
relative to the appropriate H0 and HA. Based on the form
of H0 and HA, gene set testing methods are generally
grouped into two main categories: self-contained tests
and competitive tests [5, 13]. For self-contained tests, the
null asserts that none of the gene set members have an
association with the outcome, and for competitive tests,
the null asserts that the members of the gene set are
no more associated with the outcome than genes not
in the set. In general, tests based on a competitive null
hypothesis are viewed as more biologically relevant, and
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thus are far more commonly used, than those based on a
self-contained null [5].
Although most applications of gene set testing involve
a supervised model, a number of important unsuper-
vised use cases exist, where unsupervised implies that
testing is performed in the absence of an outcome vari-
able. Important unsupervised gene set testing use cases
include case-only analyzes and p-value weighting [14],
which is explained in greater detail in the next paragraph.
In prior work, we addressed the lack of effective unsuper-
vised gene set testing techniques by developing the Spec-
tral Gene Set Enrichment (SGSE) method [15] (see the
SGSE paper for a detailed review of existing unsupervised
approaches). The SGSE method computes unsupervised
enrichment for each gene set via the association between
gene set members and the principal components (PCs)
of a genomic data set using the Principal Component
Gene Set Enrichment (PCGSE) method [16] while taking
into account the statistical significance of the eigenvalue
associated with each PC according to a Tracy-Widom
test [17].
One unsupervised use case of particular importance to
the SGSEmethod, and the work detailed in this paper, is p-
value weighting [14]. P-value weighting aims to reduce the
burden on statistical power incurred by multiple hypothe-
sis correction (MHC) by weighting the p-values computed
for each hypothesis using weights that reflect the likeli-
hood that the alternative hypothesis (HA) is true. As long
as the weights are independent of the test statistics under
the null hypothesis (H0), MHC methods will correctly
maintain either the family-wise error rate (FWER) or false
discovery rate (FDR). When p-value weighting is used
with FDR methods, e.g., the Benjamini and Hochberg
(BH) [18] method, the technique is referred to as weighted
FDR control (wFDR). In the special case where the weights
are binary, this approach is called screening-testing [19]
and has the effect of selecting and testing just a subset of
the original family of hypotheses.
Although widely applied for gene-environment inter-
action detection [20–23], p-value weighting can have a
significant impact on gene set testing power given the
significant growth in the size of common gene set collec-
tions, e.g., even the very selective Molecular Signatures
Database (MSigDB) [8] now includes over 10,000 sets. For
such large gene set collections, MHC can lower statistical
power so substantially that it becomes impossible to iden-
tify true associations for many genomic data sets [24]. The
link between p-value weighting and unsupervised gene set
testing is based on the fact that an effective way to ensure
the independence between data-driven weights and stan-
dard gene set test statistics under H0 is to ignore the
outcome variable when computing the weight, i.e., base
the weight on an unsupervised gene set test. In previ-
ously published research building on the SGSE method,
we developed a screening-testing framework for gene set
testing, called Spectral Gene Set Filtering (SGSF) [24], that
computes binary weights using the p-values generated by
the SGSE method.
Although it can be proven that weights based on an
unsupervised gene set test (like the SGSE method) will
be independent of common gene set test statistics under
H0 (see proof in the Supplemental Material for [24]), this
independence only ensures type I error control. To actu-
ally improve statistical power, the weight must also be
associated with the test statistic under HA. For gene set
testing, producing a data-driven weight therefore requires
the use of an unsupervised test that can effectively identify
the gene sets truly associated with the outcome of interest.
As illustrated in the SGSF paper [24], statistics based on
deviation from an identity population covariance struc-
ture represent a useful class of gene set weights that boost
gene sets according to the empirical correlation among
member genes. Although it is possible some biologically
important gene sets exhibit little inter-gene correlation,
it has been shown that groups of highly correlated genes
are often associated with biological processes that play
an important role in the measured experiment [11]. For
example, the genes belonging to biological pathways have
well characterized interactions and, if the pathway is
active in a given experiment context, can be expected
to exhibit correlated expression. This property is in fact
used as the basis for computationally generating many
gene sets, e.g., the MSigDB C4 cancer models [8, 25] were
created via clustering of gene expression data.
While the output of the SGSE method is effective at
identifying enriched gene sets for many use cases, there
are several biologically important scenarios represented
by non-identity covariance structures where the SGSE
method will fail to select the gene sets truly associ-
ated with the output. For example, if different subgroups
of a gene set are associated with different PCs or if
all gene set members are associated with the same PC
but the direction of association varies for different sub-
groups, the SGSE method, as well as unsupervised meth-
ods based on clustering of the genomic variables [26–28],
will perform poorly. Such scenarios are biologically
important and reflect many large gene sets associated
with processes or pathways comprised by multiple dis-
tinct groups of genes where the action of the subgroups is
either uncorrelated or counterbalancing (these use cases
are represented by the multi-block and anti-correlated
multi-block covariance structures, as detailed in Section
“Simple covariance structure examples”). Another impor-
tant limitation of the SGSE method is the fact that it only
supports a competitive H0 and therefore cannot be used
in cases where a self-contained test is of greater biologi-
cal interest (see Sections “Self-contained gene set testing”
and “Competitive gene set testing” below for detailed
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definitions of self-contained and competitive gene set
tests).
To address the shortcomings of existing unsupervised
tests and to support both self-contained and competitive
tests across a wider range of biologically relevant data
models, we have developed two novel unsupervised gene
set tests, the Marc˘enko-Pastur Distribution Test (MPDT)
and the Tracy-Widom Test (TWT) that are based on
the covariance structure of the measured genomic vari-
ables. Although a number of existing gene set testing
methods are also based on covariance structure analysis
(e.g., GSCA by Choi and Kendziorski [29], GSNCA by
Rahmatallah et al. [30] , and GSA-SDR by Hsueh and Tsai
[31]), with the exception of the SGSEmethod [15] and ear-
lier cluster-based approaches [26–28], these methods are
all supervised and identify interesting gene sets according
to difference in the covariance structure between lev-
els of a phenotype. The supervised nature of these tests
means they cannot be used to support p-value weighting,
case-only analyses or other unsupervised use cases.
Both the MPDT and TWT methods are based on ran-
dom matrix theory (RMT) findings regarding the distri-
bution of the eigenvalues of matrices with a whiteWishart
distribution [32, 33], i.e., the distribution of the sam-
ple covariance matrix for multivariate normal data with
an identity population covariance matrix. As detailed in
Section “Random matrix theory (RMT) benefits” below,
these tests were based on RMT to provide better support
for high-dimensional data, non-normal data and data
based on small sample sizes. For MPDT, the test is based
on the Marc˘enko-Pastur quarter-circle law characterizing
the limiting empirical distribution of all of the eigenval-
ues of a white Wishart matrix. For TWT, the test is based
on the Tracy-Widom law of order 1 characterizing the
limiting distribution of the largest eigenvalue of a white
Wishart matrix. Versions of the MPDT and the TWT are
detailed in Section “Methods” for both self-contained and
competitive null hypotheses. For the self-contained case,
we contrast our proposed tests with the classic multi-
variate test based on a modified likelihood ratio criterion
(MLRT) and, for the competitive case, we compare the
new tests against a competitive version of the classic test
and our SGSE method (also based on RMT).
As we demonstrate through simulation studies, the
MPDT and TWTmethods provide superior performance
relative to the MLRT and SGSE methods on several bio-
logically important covariance structures (e.g., the multi-
block and anti-correlated multi-block structures detailed
in Table 1). The practical utility of the TWT and MPDT
methods is illustrated through a weighted FDR analysis of
leukemia [34] and p53 [4] gene expression data sets rel-
ative to MSigDB gene set collections [8]. The remainder
of this paper is organized as follows: Section “Methods”
specifies the statistical properties of the MPDT and
TWT methods, models for important use cases, simu-
lation study design and approach for real data analysis,
Section “Results” contains the results of the simulation
studies and real data analyses and Section “Discussion”
provides a discussion. Additional file 1 contains additional
results for the real data analysis.
Methods
Data assumptions
It is assumed that measurements have been made for
p genomic variables under n independent experimental
conditions, e.g., expression levels of p mRNA molecules
within tissue samples from n subjects. This data will be
modeled as a sample of n independent observations from
a p-dimensional random vector xwithmeanμ and covari-
ance . Although the unsupervised gene set tests devel-
oped in this paper are robust to deviations from normality
(see Section “Random matrix theory (RMT) benefits”
below for details), it will be assumed that x can be well
approximated by a multivariate normal distribution after
appropriate transformation, i.e., x ∼ N (μ,). This data
can be held in an n × p matrix X whose elements xi.j rep-
resent the measured value of genomic variable j under
condition i. Let C represent the mean-centered version
of X.
It is assumed that the p genomic variables have been
annotated to a collection of f biologically-based sets
of genomic variables or gene sets, e.g., Gene Ontol-
ogy (GO) terms [6]. These annotations can be held in
a f × p binary annotation matrix A whose rows rep-
resent the f biologically-based sets and whose cells ai,j
hold indicator variables whose value depends on whether
an annotation exists between gene set i and genomic
variable j.
For a given gene set, i, the p variables can be parti-
tioned into two sets, pg and pc, according to the indicator
variables in row i of matrix A with pg containing all vari-
ables that are members of the gene set, pc containing the
complement of the gene set and p∗ representing the set
of all p variables. Let the number of variables in subset
pg be represented by g and the number in pc be repre-
sented by c = p − g. If the variables are reordered such
that the variables in the gene set, i.e., pg , are listed before
the variables not in the gene set, i.e., pc, the population,




pg ,pg pg ,pc
pc,pg pc,pc
]
, S = 1nC
TC =
[
Spg ,pg Spg ,pc
Spc ,pg Spc ,pc
]
(1)
This same partitioning can be applied to the population
and sample correlation matrices.
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Self-contained gene set testing
For a self-contained gene set test, only the genomic vari-
ables that are members of the gene set may be used to
compute the test statistic. Informally, the null hypothesis
for an unsupervised and self-contained test asserts that
none of the genomic variables in the gene set, i.e., pg , are
enriched relative to the genomic data matrix Xmore than
would be expected at random. Importantly, in an unsuper-
vised context this measurement of gene set enrichment
is defined with respect to the distribution of the random
vector x and not with respect to the association between
the members of x and some other covariate.
Given the partitioning of the population and sample
covariance matrices specified in (1), one possible formu-
lation of an unsupervised and self-contained gene set
test measures enrichment as departure from a null dis-
tribution of N (μg , I) for the pg variables in the gene set.
This can be formally defined using the following null and
alternative hypotheses:
H0 : pg ,pg = I,HA : pg ,pg = I (2)
Under this null hypothesis, nSpg ,pg has a white Wishart
distribution,W(n−1, I), i.e., aWishart distribution where
the population covariance matrix is equal to the identity
matrix.
In Sections “Classic modified likelihood ratio test
(MLRT)” – “Self-contained Marc˘enko-Pastur Distribu-
tion Test (MPDT)” below, three different tests of these
hypotheses are described, each based on the null distribu-
tion of a test statistic Tself that is a function of X and pg .
The test detailed in Section “Classic modified likelihood
ratio test (MLRT)” is the classic test of  = I from mul-
tivariate statistics. Sections “Self-contained Tracy-Widom
Test (TWT)” and “Self-contained Marc˘enko-Pastur Dis-
tribution Test (MPDT)” describe self-contained versions
of two new unsupervised gene set tests, the Marc˘enko-
Pastur Distribution Test (MPDT) and the Tracy-Widom
Test (TWT). Both the MPDT and the TWT are based
on random matrix theory (RMT) findings regarding the
distribution of the eigenvalues of matrices with a white
Wishart distribution [32, 33].
It is important to note that, for practical applications,
rejection of the null hypothesis (2) at a given α may be
of little interest to researchers given the limited biolog-
ical information provided by self-contained tests and
the general sensitivity of such tests to small deviations
from the null [5]. As a consequence, gene set testing
is almost always performed against a competitive null
hypothesis. The self-contained tests described in Sections
“Classic modified likelihood ratio test (MLRT)” through
“Self-contained Marc˘enko-Pastur Distribution Test
(MPDT)” were therefore developed primarily to pro-
vide statistics for use in competitive tests, as detailed in
Section “Competitive gene set testing” below.
Classic modified likelihood ratio test (MLRT)
The classic test of self-contained hypotheses (2) for mul-
tivariate normal data is based on a modified likelihood
ratio criterion [35]. Specifically, this criterion leads to the
following self-contained test statistic:
Tself(X, pg) = n(trace(Spg ,pg ) − log|Spg ,pg | − g) (3)
Under the asymptotic regime in which n → ∞ and g is
fixed, this statistic has a χ2 distribution with g(g + 1)/2
degrees of freedom.
Self-contained Tracy-Widom Test (TWT)
The TWT is based on the Tracy-Widom law of order
1 characterizing the limiting distribution of the largest
eigenvalue of a white Wishart matrix. Since nSpg ,pg has
a white Wishart distribution, W(n − 1, I) under the null
hypothesis (2), the Tracy-Widom result can be used as the
basis for a self-contained gene set test. Specifically, the
limiting distribution of a centered and scaled version of
the largest eigenvalue of nSpg ,pg , λˆ1, under H0 (2) is given
by the Tracy-Widom law of order 1 [17]:
lim
n,g→∞,n/g→η≥1Pr(
λˆ1 − μ(g, n)
σ (g, n) < x) = F1(x) (4)
where the scaling and centering terms are given by
μ(g, n) = (√n − 1 + √g)2 and σ(g, n) = (√n − 1 +√g) (1/(√n − 1) + 1/(√g))1/3.
The self-contained version of the TWT therefore
defines Tself as the scaled and centered version of λˆ1, as
specified in (4), and tests for deviation from the Tracy-
Widom law of order 1 distribution expected under H0 (2).
Tself(X, pg) = λˆ1 − μ(g, n)
σ (g, n) (5)
One disadvantage of the TWT is that it considers only the
principal eigenvalue of nSpg ,pg and will therefore ignore
the significance of eigenvalues λˆi, i ≥ 2.
Self-containedMarc˘enko-Pastur Distribution Test (MPDT)
The MPDT is based on the Marc˘enko-Pastur quarter-
circle law characterizing the limiting empirical distribu-
tion of all of the eigenvalues of a whiteWishart matrix [32,
33]. If it is assumed that nSpg ,pg has rank g, the empirical
distribution function of the eigenvalues, λˆi, i = 1, . . . , g, of






1(λˆi ≤ x) (6)
and the Marc˘enko-Pastur quarter-circle law holds
that limn,g→∞,g/(n−1)→γ∈(0,∞) Fλˆi(x) = G(x)
where the density of G(x) is given by g(x) =
1/(2πγ x)
√
(b+ − x)(x − b−, b± = (1 ± √γ )2. The
self-contained version of the MPDT leverages this result
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by comparing the empirical distribution function F
λˆi
(x)
(6) against the expected Marc˘enko-Pastur distribu-
tion for γ = g/(n − 1) using a two-sided, one-sample
Kolmogorov-Smirnov test. This is based on the null
distribution of a statistic, D, defined as the maximum
difference between the two distribution functions:




(x) − G(x))| (7)
This test has the benefit, relative to the TWT, of account-
ing for all of the eigenvalues of nSpg ,pg . A limitation of the
MPDT is that the λˆi are dependent, which results in an
incorrectly large degrees-of-freedom for the Kolmogorv-
Smirnov test and an inflated type I error rate unless the
dependence structure can be accurately modeled [36].
Fortunately, this inflated type I error rate is only an issue
for a strictly self-contained test. When the Tself from
the MPDT is used in a competitive test (as described in
Section “Competitive gene set testing” below), the incor-
rect degrees of freedom no longer poses a problem. This
test is therefore primarily useful as a means of ranking the
f gene sets (according to the magnitude of D (7)).
Competitive gene set testing
For competitive and unsupervised gene set tests, two pri-
mary forms of null hypothesis are possible. The first type
of competitive null asserts that a given gene set is no more
associated with X than are the other gene sets defined in
the annotation matrix A. The second type of competitive
null asserts that the members of a given gene set are no
more associated with X than would be expected for a ran-
dom set of genomic variables of the same size. Although
both forms of null hypothesis are valid and address impor-
tant biological questions, we focus solely on that later
form of competitive test in this paper. Not only does this
form of competitive null provide results for a given gene
set that are invariant to the size and composition of A
but it can easily be used as the basis for a comparative
analysis of multiple gene sets, e.g., rank the gene sets
defined in A according to the p-values from competitive
testing.
For this paper, then, the null hypothesis for an unsu-
pervised competitive gene set test informally asserts that
the genomic variables in the gene set, i.e., pg , are no more
enriched relative to the variance structure of the matrix
X than would be expected for a set of g genomic vari-
ables drawn at random from among all p variables, i.e.,
pg∈p∗ or pg∗. The one-sided alternative hypothesis of inter-
est informally asserts that the genomic variables in pg
are more enriched relative to the variance structure of
the matrix X than would be expected for a random set
of variables pg∗. These competitive hypotheses can be
formally defined in terms of the cumulative distribution
functions of the eigenvalues of the population covariance
matrices pg ,pg and pg∗,pg∗ . Specifically, under the com-
petitive H0 the eigenvalues of pg ,pg and pg∗,pg∗ have
identical cumulative distributions and, under the corre-
sponding HA, the cumulative distribution of the eigenval-
ues of pg ,pg is point-wise smaller than the cumulative
distribution of the eigenvalues of pg∗,pg∗ , i.e., distribution
of the eigenvalues ofpg ,pg is shifted towards larger values
relative to the eigenvalue distribution for pg∗,pg∗ . Math-
ematically, these competitive hypotheses can be stated as
follows:
H0 : ∀xFλi(pg ,pg )(x) = Fλi(pg∗ ,pg∗ )(x)
HA : ∀xFλi(pg ,pg )(x) ≤ Fλi(pg∗ ,pg∗ )(x)
(8)
where Fλi(pg ,pg )(x) and Fλi(pg∗ ,pg∗ )(x) represent the eigen-
value cumulative distribution functions, as defined by (6)
above, of the population covariance matrices pg ,pg and
pg∗,pg∗ . It is important to note that H0 (8) does not assert
that either pg ,pg = I or that pg∗,pg∗ = I. Instead,
the H0 (8) asserts that pg ,pg and pg∗,pg∗ have equiva-
lent eigenvalue distributions. In other words, the H0 (8)
can hold even if both pg ,pg and pg∗,pg∗ deviate signif-
icantly from the identity matrix as long as the deviation
is equivalent when characterized by the eigenvalues of
the matrices. This competitive H0 is quite distinct from
the corresponding self-contained H0 (2) that asserts an
identity population covariance matrix.
To test competitive hypotheses (8), we define compet-
itive versions of the MLRT, TWT and MPDT tests that
use the self-contained statistic Tself computed for both pg
and pg∗, where Tself is defined by either (3), (5) or (7). For
these competitive tests, statistical significance relative to
the competitive hypotheses (8) is computed using the fol-
lowing permutation testing procedure for each gene set
defined in A:
• Compute Tself(X, pg) according to (3), (5) or (7).
• From among all (pg) possible combinations of g
variables from the set of all p variables, select B
random combinations.
• For each combination, pb, b = 1, . . . ,B, compute
Tself(X, pb) according to (3), (5) or (7).
• Use the permutation distribution of Tself(X, pb) to
compute the p-value for hypotheses (8):
Pr(Tself(X, pg∗) > Tself(X, pg)|H0)
=
∑B
b=1 1(Tself(X, pb) > Tself(X, pg))
B
(9)
For standard gene set testing, i.e., testing in a supervised
context, the use of such a gene-level permutation distribu-
tion, i.e., a distribution generated by permuting the assign-
ment of genes to gene sets, is problematic and can lead to
an inflated type I error rate [11]. Specifically, because the
permutation distribution breaks the correlation structure
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of the gene set, the permutation distribution of a super-
vised gene set test statistic (i.e., a statistic that reflects the
association of set members with an outcome variable) will
have a much smaller variance than the true null distri-
bution of the gene set test statistic given the correlation
present among gene set members. As an example, sup-
pose the supervised gene set statistic is the mean of the
t statistics capturing association between genomic vari-
ables in the set and a binary outcome. If the members
of a gene set are correlated, then the true null distri-
bution of this gene set statistic has expectation 0 but a
variance that is much larger than the variance of the statis-
tic computed under the permutation null distribution. In
an unsupervised context, however, breaking the correla-
tion between gene set members through the permutation
test does not pose a problem since the analysis is focused
on the variance structure of the gene set members and
not on their association with an outcome variable. In this
case, the competitive null asserts a correlation structure
among gene set members that matches what is generated
through permutation, i.e., under H0 (8) the correlation
structure for a gene set matches the correlation structure
for a random sample of the same size.
Randommatrix theory (RMT) benefits
The development of the RMT-based MPDT and TWT
methods was motivated by three key factors (which
we validate and quantify through the simulation studies
described in Section “Evaluation design”):
1. Asymptotic regime: The classic test holds under the
standard asymptotic regime in which n → ∞ while p
is fixed. The RMT-based tests, on the other hand,
hold under an asymptotic regime where both n and
p → ∞ while the ratio p/n → γ ∈ (0,∞).
Importantly, RMT asymptotics can be expected to
provide a more accurate approximation of genomic
data than standard asymptotics [37].
2. Deviation from normality: Although both the classic
test and the RMT-based tests are derived under the
assumption of multivariate normality for x, the
RMT-based tests, due to the universality properties
of the RMT distributions, can be expected to be more
robust to deviations from normality for the elements
of x [38]. Such distributional robustness is especially
important in the context of gene set testing of genetic
variation data, e.g., genome-wide association data
capturing single nucleotide polymorphisms (SNPs).
3. Small sample size: Although both the classic test and
the RMT-based tests are asymptotic approximations,
the RMT-based tests can be expected to perform
better for very small samples sizes, e.g., Johnstone
found that the distribution of the largest eigenvalue
of a white Wishart matrix was well approximated by
the Tracy-Widom law of order 1 for data sets as
small as p = 5 and n = 20 [17].
Simple covariance structure examples
The behavior of the self-contained and competitive tests
outlined in Sections “Self-contained gene set testing”
and “Competitive gene set testing” above can be illus-
trated using simple, but biologically meaningful, use cases
based on different population covariance matrix struc-
tures. These covariance structures, along with expected
results for the self-contained and competitive tests, are
shown in Table 1 using the partitioning from Section
“Data assumptions”. For simplicity, it is assumed that there
is only one gene set containing the first p/2 genomic vari-
ables. Examples where the two tests give different answers
are in bold. These covariance structures are referenced in
Sections “Simulation design to assess type I error control”,
“Simulation design to assess statistical power” and
“Discussion” to characterize the simulation designs
and discuss the relative performance of the evaluated
methods.
Evaluation design
Benchmark unsupervised and competitive gene set tests
For comparative evaluation of the competitive versions
of the TWT and MPDT methods outlined in Sections
“Self-contained gene set testing” and “Competitive gene
set testing”, two benchmark unsupervised gene set tests
were used: the classic modified likelihood ratio test
(MLRT) and the Spectral Gene Set Enrichment (SGSE)
[15] method. For the MLRT test, competitive testing
used the classic modified likelihood ratio test statis-
tic detailed in Section “Classic modified likelihood ratio
test (MLRT)” with the competitive permutation proce-
dure outlined in Section “Competitive gene set testing”.
For all simulation and real data analyses detailed in this
paper, the SGSE method was executed using all PCs
with non-zero eigenvalues, gene-level test statistics set
to the Fisher-transformed Pearson correlation coefficients
between each gene and each PC, statistical association
between each PC and each gene set computed using a
correlation-adjusted two-sample t-test between the gene-
level test statistics for gene set members and non-gene set
members and overall unsupervised gene set association
computed using the weighted Z-method on the PC-level
p-values with weights set to the PC variance multiplied
by the lower-tailed p-value from a Tracy-Widom test on
that PC eigenvalue. See the original SGSE paper [15] for
more information on the operation and configuration of
the method.
Simulation design to assess type I error control
To assess type I error control for the competitive ver-
sions of the MPDT and TWT methods, as detailed in
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Table 1 Covariance structure examples






⎦ Accept H0 Accept H0





⎦ Reject H0 Accept H0
















⎥⎥⎥⎦ Reject H0 Reject H0










⎥⎥⎥⎦ Reject H0 Reject H0





⎦ Accept H0 ∗Accept H0





⎦ Reject H0 ∗Reject H0





⎦ Reject H0 Accept H0
Examples where the self-contained and competitive tests give different answers are in bold. For the inverted single block structure, a two-sided competitive null would be
rejected whereas the one-sided competitive HA would be accepted. For the repeated block structure, H0 will be rejected since a random sample of g genes from among all p
genes will likely include some pairs with 0 covariance
Section “Competitive gene set testing”, and the two bench-
mark competitive methods listed in Section “Benchmark
unsupervised and competitive gene set tests”, data were
simulated according to eight null simulation designs as
outlined in Table 2 (seven for multivariate normal data
and one for multivariate binomial data). In Table 2, the
covariance structure column refers to one of the models
listed in Table 1, p represents the total number of simu-
lated genes, n represents the number of independent sam-
ples in each data set, g represents the size of each disjoint
Table 2 Simulation designs for type I error
Type I error design # Covariance structure g p n σ 2 ρ
MVN-1 Identity 10 100 100 1 0
MVN-2 Scaled Identity 10 100 100 2 0
MVN-3 Compound symmetry 10 100 20 1 0.1
MVN-4 Compound symmetry 10 100 50 1 0.1
MVN-5 Compound symmetry 10 100 100 1 0.1
MVN-6 Compound symmetry 10 100 100 2 0.1
MVN-7 Compound symmetry 10 100 100 1 0.2
Binomial-1 Compound symmetry 10 100 100 0.375 0.1
Simulation design models for assessing type I error control using a multivariate
normal distribution (MVN-1 thru MVN-7) or a multivariate binomial (n=2, p=0.25)
distribution (Bionomial-1) for x
gene set, σ 2 represents the variance for all variables and
ρ represents the pairwise covariance between all genes
(i.e., all gene pairs have the same covariance irrespec-
tive of gene set membership). The multivariate binomial
distribution was included tomimic single nucleotide poly-
morphism (SNP) data specified using additive coding. For
all designs, 1,000 data sets were simulated and tested for
unsupervised enrichment against a gene set annotation
matrix A that defined p/g disjoint gene sets each contain-
ing g genes. For the competitive versions of the MLRT,
MPDT and TWT methods, the number of permutations
B was set to 500. For SGSE, all g principal components
were used and other method parameters were specified as
detailed in Section “Benchmark unsupervised and comp-
etitive gene set tests”.
Simulation design to assess statistical power
To assess statistical power for the four evaluated methods,
data was simulated according to ten different simulation
designs outlined in Table 3 (nine designs for multivariate
normal data and one for multivariate binomial data). The
motivation and implications of each simulation model are
discussed in more detail in Sections “Unsupervised gene
set testing for the single block model” – “Unsupervised
gene set testing for the single block model” below. With
the exception of the σ 2 and ρ columns, the columns in
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Table 3 Simulation designs for statistical power
Power design # Covariance structure g p n σ 2 ρ
MVN-1 Single block 10 100 100 1 0.1
MVN-2 Single block 10 100 50 1 0.1
MVN-3 Single block 10 100 20 1 0.1
MVN-4 Single block 10 100 100 1 0.15
MVN-5 Single block 10 100 100 1.1 0
MVN-6 Single block 10 100 100 1.15 0
MVN-7 Multi-block 10 100 100 1 0.2/0
MVN-8 Anti-cor. multi-block 10 100 100 1 0.1/-0.1
MVN-9 Repeated block 10 100 100 1 0.1
Binomial-1 Single block 10 100 100 0.375 0.1
Simulation designs for assessing statistical power using a multivariate normal
distribution (MVN-1 thru MVN-9) or multivariate binomial (n=2, p=0.25) distribution
(Binomial-1) for x
Table 3 have the same interpretation as the correspond-
ing columns in Table 2, as detailed in Section “Simulation
design to assess type I error control” above. For Table 3,
σ 2 represents the variance of members of the non-null
gene sets (a variance of 1 was used for all genes in null
sets) and ρ represents the pairwise covariance between
the members of non-null gene sets. All models listed
in Table 3 included just a single non-null gene set with
the exception of model MVN-9, for which all 10 disjoint
gene sets were non-null. For model MVN-7, the non-
null gene set was divided into 5 disjoint sub-blocks of
size 2 with a covariance of 0.2 between the two members
of each sub-block and 0 covariance between members
of different sub-blocks. For model MVN-8, the non-null
gene set was divided into two 5 member sub-blocks with
pairwise covariance between sub-block members of 0.1
and pairwise covariance between members of different
sub-blocks set to -0.1. Similar to the simulation proce-
dure for assessing type I error control outlined in Section
“Simulation design to assess type I error control”, 1,000
data sets were simulated for each of the ten designs and
tested for unsupervised enrichment against a gene set
annotation matrix A that defined one truly enriched gene
set containing the first 10 variables. Configuration of the
MLRT, MPDT, TWT and SGSE methods mirrored the
settings specified for the type I error control simulations.
Real data analysis design
To demonstrate the practical utility of the proposedmeth-
ods, gene set testing was performed using a weighted
FDR approach [14] on two classic gene expression data
sets relative to v5.0 of the MSigDB gene set collections
[8]. Specifically, the following MSigDB collections were
tested: c1.all (positional), c2.cpg (curated: chemical and
genetic perturbations), c2.cp (curated: canonical path-
ways), c3.mir (motif: microRNA targets), c3.tft (motif:
transcription factor targets), c4.cgn (computational: can-
cer gene neighborhoods), c4.cm (computational: cancer
modules), c5.bp (GO: biological process), c5.cc (GO: cel-
lular component), c5.mf (GO: molecular function), c6.all
(oncogenic signatures), c7.all (immunologic signatures).
Prior to analysis, each MSigDB collection was filtered
to remove gene sets with less than 5 or more than 200
members.
For the evaluations detailed in this paper, the pro-
posed unsupervised gene set testing methods (TWT
and MPDT) and the benchmark methods (SGSE and
MLRT) were used to generate weights that were applied
to the p-values generated via supervised gene set testing
using the CAMERA method [11]. The weighted CAM-
ERA p-values were then subjected to a wFDR analysis
using the Benjamini and Hochberg (BH) [18] method.
See Section “Configuration of CAMERA method for real
data analysis” below for further details on the CAMERA
method and the configuration settings used for these anal-
yses. As detailed in Genovese et al. [14], the BH method
provides valid FDR control when applied to a set of
weighted p-values as long as the weights have an aver-
age value of 1 and are independent of the p-values under
H0. To meet these requirements, the weights were based
on the -log of the p-values generated by the evaluated
competitive unsupervised gene set testing methods. If ui
represents the p-value from the unsupervised test for gene
set i (out of a total of f gene set tests), the weights,wi, were
calculated as wi = −log(ui)/(1/f ∑fj=1 −log(uj)), which
ensures that
∑f
i=1 wi = f . If si represents the p-value from
the CAMERA supervised test for gene set i, weighted p-
values were then computed as s∗i = wisi with the wFDR
q-values computed using the standard BHmethod applied
to s∗i .
For TWT, MPDT and MLRT, the number of permuta-
tions B for competitive testing was set to 5000. For SGSE,
all PCs associated with non-zero eigenvalues were used
and othermethod parameters were specified as detailed in
Section “Benchmark unsupervised and competitive gene
set tests”. The two classic gene expression data sets ana-
lyzed were the Armstrong et al. [34] leukemia gene expres-
sion data set and the p53 gene expression data set used in
the 2005 GSEA paper [4]. These data sets were selected
because of their easy accessibility and extensive use in the
gene set testing literature [4, 9], factors that will allow
other researchers to more easily replicate and interpret
the results outlined in this paper. Similarly, v5.0 of the
MSigDB collections were chosen for analysis due to their
accessibility and high quality annotations.
Configuration of CAMERAmethod for real data analysis
CAMERA [11] is a two-stage, competitive gene set testing
method that adjusts for the correlation between gene set
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members. CAMERA performs gene set testing using the
following approach:
1. Model the relationship between the genomic
variables xi, i = 1, . . . , p and phenotype y using a
series of p univariate linear models of the form
xi ∼ β0 + β1y + ε. If multiple phenotype variables
exist, a contrast of model coefficients must also be
specified.
2. Compute gene-level test statistics, zi, i = 1, . . . , p,
from each of the p univariate models. The t-statistic
associated with βˆ1 is a typical choice. CAMERA uses
a normalized t-statistic.
3. Use the gene-level test statistics to generate gene set
test statistics, Sj, for each of the gene sets in the
target collection. The mean difference test statistic,
which follows a t-distribution under H0, is a common
choice: Sj = (z¯j − z¯jc)/(σp
√
1
mj − 1p−mj ), wheremj is
the number of genomic variables in set j, z¯j is the
mean of the zi for members of gene set j, z¯jc is the
mean of the zi for genes not in set j and σp is the
pooled standard deviation of the zi. CAMERA uses a
correlation-adjusted version of the mean difference
statistic.
4. Determine the statistical significance of the
gene-level test statistics under null hypothesis that
the zi for genomic variables in the gene set are
identically distributed to the zi for genomic variables
not in the gene set. CAMERA determines statistical
significance using a two-sample t-test on the
correlation-adjusted mean difference statistic. Many
other two-stage competitive gene set testing methods
use permutation of y to calculate a p-value.
For enrichment of the MSigDB gene set collections
relative to the leukemia and p53 data, CAMERA was
executed with default settings and gene-wise test statis-
tics (zi above) calculated via the linear regression of
the gene expression value on a data set specific phe-
notype. For the leukemia data, the phenotype was the
acute myeloid leukemia (AML) versus acute lymphoblas-
tic leukemia (ALL) status while for the p53 data the
phenotype was the p53 mutated status. For both data sets,
false discovery rate (FDR) values were computed using




Type I error control results
Results from the type I error simulation studies detailed in
Section “Simulation design to assess type I error control”
are shown in Table 4. As listed in Table 4, type I error
Table 4 Average type I error rate
# Cov. struct., n, σ 2, ρ TWT MPDT MLRT SGSE
MVN-1 Identity, 100, 1, 0 0.049 0.049 0.050 0.050
MVN-2 Scaled Identity, 100, 2, 0 0.050 0.045 0.049 0.052
MVN-3 Compound sym., 20, 1, 0.1 0.053 0.051 0.051 0.049
MVN-4 Compound sym., 50, 1, 0.1 0.049 0.045 0.048 0.051
MVN-5 Compound sym., 100, 1, 0.1 0.046 0.051 0.051 0.051
MVN-6 Compound sym., 100, 2, 0.1 0.048 0.051 0.048 0.046
MVN-7 Compound sym., 100, 1, 0.2 0.049 0.049 0.052 0.050
Binom-1 Compound sym., 100, 1, 0.1 0.044 0.054 0.053 0.048
Average type I error rate for each of the evaluated competitive methods computed
on 1000 simulated data sets for the eight simulation designs detailed in Table 2
control was excellent for all evaluatedmethods on all eight
null simulation designs.
Power results
Results from the power simulation studies detailed in
Section “Simulation design to assess statistical power” are
shown in Table 5. Although no single competitive method
was superior for all models, the TWT method had the
best overall performance with the largest average power
for six of the ten simulations and close to the best power
for the remaining four models. While the TWT method
was the most powerful in the majority of the use cases,
each of the tested methods had the best power for at
least one of the tested models. In all cases, the average
relative power of the four methods was consistent with
the expected behavior of the methods for the simulated
covariance structures. Sections “Unsupervised gene set
testing for the single block model” thru “Unsupervised
gene set testing for non-normal data” below contain more
detailed discussions of the results for each of these ten
models.
Real data results
As outlined in Section “Real data analysis design”, the
proposed and benchmark methods were evaluated via a
wFDR analysis of leukemia [34] and p53 [4] gene expres-
sion data sets relative to 12 of theMSigDB v5.0 collections.
For these analyses, the results of the unsupervised test
were used to weight the p-values generated by supervised
gene set testing. Table 6 contains the results for the C7 col-
lection (immunologic signatures) relative to the leukemia
data and Table 7 contains the results for the C6 collec-
tion (oncogenic signatures) relative to the p53 data. The
first column in each table contains the gene set name with
the number of genes in the set in parentheses. The sec-
ond column lists the direction of enrichment, the third
column ("GSE p-value) contains the enrichment signifi-
cance as computed via the supervised CAMERA method
and the forth column (“Unfiltered q-value”) holds the false
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Table 5 Average empirical power
# Cov. struct, n, σ 2, ρ TWT MPDT MLRT SGSE
MVN-1 Single block, 100, 1, 0.1 0.87 0.35 0.79 0.76
MVN-2 Single block, 50, 1, 0.1 0.52 0.20 0.42 0.55
MVN-3 Single block, 20, 1, 0.1 0.24 0.16 0.18 0.37
MVN-4 Single block, 100, 1, 0.15 0.99 0.66 0.97 0.95
MVN-5 Single block, 100, 1.1, 0 0.41 0.38 0.16 0.10
MVN-6 Single block, 100, 1.15, 0 0.63 0.68 0.29 0.10
MVN-7 Multi-block, 100, 1, 0.2/0 0.31 0.28 0.56 0.19
MVN-8 Anti-cor. multi-block, 100, 1, 0.1/-0.1 0.85 0.32 0.74 0.06
MVN-9 Repeated block, 100, 1, 0.1 0.49 0.11 0.23 0.10
Binom-1 Single block,100, 1, 0.1 0.64 0.02 0.26 0.55
Average empirical power for each of the evaluated competitive methods computed on 1000 simulated data sets for the ten simulation designs detailed in Table 3. The
largest average power found for each design is listed in bold
Table 6 Leukemia gene expression results
Gene set Direction GSE Unweighted MLRT SGSE TWT MPDT
p-value q-value wFDR wFDR wFDR wFDR
*GSE10325_{B}CELL_{V}S_{M}YELOID_{U}P (124) ALL 0.00225 0.999 0.655 0.711 0.0969 1
*GSE29618_{B}CELL_{V}S_{M}ONOCYTE_{D}AY. . . (130) ALL 0.00302 0.999 0.655 0.711 0.0969 1
GSE29618_{B}CELL_{V}S_{M}DC_{D}AY7_{F}LU. . . (126) ALL 0.0046 0.999 0.655 0.729 0.574 1
GSE10325_{C}D4_{T}CELL_{V}S_{B}CELL_{D}N (132) ALL 0.005 0.999 1 0.711 0.574 1
*GSE10325_{L}UPUS_{B}CELL_{V}S_{L}UPUS_. . . (123) ALL 0.00563 0.999 0.431 0.711 0.12 1
GSE29618_{B}CELL_{V}S_{M}DC_{U}P (133) ALL 0.00719 0.999 0.655 0.955 0.574 1
GSE29618_{B}CELL_{V}S_{M}ONOCYTE_{U}P (108) ALL 0.00776 0.999 0.655 0.711 0.574 1
GSE29618_{B}CELL_{V}S_{M}ONOCYTE_{D}AY. . . (143) AML 0.0137 0.999 0.655 0.711 0.574 1
GSE24634_{T}REG_{V}S_{T}CONV_{P}OST_{D}A. . . (123) AML 0.0162 0.999 1 0.711 1 1
GSE6269_{H}EALTHY_{V}S_{S}TREP_{A}UREU. . . (133) AML 0.0168 0.999 0.655 0.711 0.574 1
GSE29618_{B}CELL_{V}S_{M}DC_{D}AY7_{F}LU. . . (126) AML 0.0171 0.999 0.655 0.711 1 1
GSE6269_{H}EALTHY_{V}S_{S}TREP_{P}NEUM. . . (134) AML 0.0174 0.999 0.655 0.711 0.742 1
GSE15767_{M}ED_{V}S_{S}CS_{M}AC_{L}N_{U}P (117) AML 0.0229 0.999 1 0.711 1 1
GSE6269_{E}_COLI_{V}S_{S}TREP_{A}UREUS. . . (130) AML 0.0245 0.999 1 0.711 1 1
GSE22886_{N}AIVE_{C}D8_{T}CELL_{V}S_{N}E. . . (122) AML 0.0295 0.999 1 0.729 1 1
GSE6269_{F}LU_{V}S_{E}_COLI_{I}NF_{P}BMC. . . (128) AML 0.0306 0.999 1 0.711 1 1
GSE29618_{M}ONOCYTE_{V}S_{P}DC_{U}P (126) AML 0.0333 0.999 0.659 0.711 0.706 1
GSE6269_{H}EALTHY_{V}S_{S}TREP_{A}UREU. . . (109) ALL 0.0353 0.999 0.906 0.907 0.592 1
GSE3982_{M}EMORY_{C}D4_{T}CELL_{V}S_{B}C. . . (73) ALL 0.0361 0.999 1 0.995 1 1
GSE360_{C}TRL_{V}S_{M}_TUBERCULOSIS_. . . (71) AML 0.0364 0.999 1 0.711 1 1
GSE11057_{E}FF_{M}EM_{V}S_{C}ENT_{M}EM_{C}. . . (85) AML 0.0381 0.999 1 0.729 1 1
GSE10325_{L}UPUS_{B}CELL_{V}S_{L}UPUS_. . . (88) AML 0.0384 0.999 0.655 0.711 0.998 1
GSE360_{C}TRL_{V}S_{L}_DONOVANI_{D}C_{D}. . . (75) AML 0.0403 0.999 1 0.729 1 1
GSE22886_{N}AIVE_{C}D4_{T}CELL_{V}S_{N}E. . . (92) AML 0.0403 0.999 1 0.758 1 1
GSE3982_{C}TRL_{V}S_{P}MA_{S}TIM_{E}OSIN. . . (93) AML 0.0427 0.999 1 0.711 1 1
Results for the MSigDB C7 v5.0 collection and the Armstrong et al. [34] leukemia gene expression data (1910 total gene sets after size-based filtering). Significant q-values are
marked in bold with a *before the gene set name
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discovery rate q-value based on the unweighted super-
vised GSE p-values. Columns five through eight display
the q-values from a wFDR analysis using each of the eval-
uated unsupervised gene set testing methods to compute
the p-value weight.
The Additional file 1 contains similar results for all
of the collections for both data sets. The Additional
file 1 also contains the Spearman rank correlation val-
ues between the unsupervised gene set testing p-values
computed by the CAMERA method and various unsu-
pervised statistics (mean inter-gene correlation and the
p-values from the MLRT, SGSE, TWT and MPDT meth-
ods). As seen in Tables 6 and 7 and the Additional file 1, no
single method was dominant for all MSigDB collections
on both data sets, however, the TWT method and SGSE
method tended to provide the best overall results. The
rank correlation values shown in Tables S1 and S14 of the
Additional file 1 also demonstrate the general association
between gene set biological activity (as represented by the
CAMERA gene set test p-values) and the sample covari-
ance structure of the gene set members. Section “Perfor-
mance on gene expression data and MSigDB collections”
below contains a more detailed discussion of the real data
analysis results.
Discussion
Gene set testing, or pathway analysis, is an important tool
for analyzing and interpreting high-dimensional genomic
data sets [1, 2]. Compared to approaches that use a sep-
arate test for each variable, gene set testing offers greater
statistical power, superior interpretation and improved
replication. Although most gene set testing methods can
only be used in a supervised context, i.e., assessing the
association of gene set members with an outcome vari-
able, a number of important unsupervised use cases
exist. To address the lack of effective unsupervised gene
set testing methods, we recently developed the SGSE
method [15] and later demonstrated the effective use
Table 7 p53 gene expression results
Gene set Direction GSE Unweighted MLRT SGSE TWT MPDT
p-value q-value wFDR wFDR wFDR wFDR
∗P53_DN.V1_UP (10) MUT 5.21e-09 9.79e-07 1.43e-07 6.53e-07 1.31e-06 1.09e-05
∗P53_DN.V1_DN (14) WT 8.67e-07 8.15e-05 1.19e-05 9.56e-05 6.96e-06 1.09e-05
RB_P130_DN.V1_DN (123) MUT 0.0342 0.914 1 0.505 1 1
BCAT.100_UP.V1_UP (103) MUT 0.0385 0.914 1 0.517 1 1
∗VEGF_A_UP.V1_DN (114) MUT 0.0432 0.914 0.315 0.505 0.231 1
EGFR_UP.V1_DN (136) MUT 0.046 0.914 0.315 0.505 1 0.989
RB_DN.V1_DN (110) MUT 0.056 0.914 1 0.505 1 1
∗CORDENONSI_YAP_CONSERVED_SIGNA... (124) MUT 0.0593 0.914 0.324 0.505 0.238 0.208
RAF_UP.V1_UP (98) MUT 0.0597 0.914 0.873 0.505 1 1
SRC_UP.V1_UP (98) WT 0.0604 0.914 1 1 1 1
∗RPS14_DN.V1_DN (98) MUT 0.0651 0.914 1 0.734 1 0.208
HOXA9_DN.V1_DN (105) MUT 0.0685 0.914 1 0.505 1 1
CSR_EARLY_UP.V1_UP (159) MUT 0.0719 0.914 0.958 0.505 1 1
TBK1.DF_DN (150) MUT 0.0797 0.914 1 0.56 1 1
EGFR_UP.V1_UP (17) MUT 0.0832 0.914 0.332 0.517 1 1
MEK_UP.V1_UP (9) MUT 0.085 0.914 0.332 0.505 1 1
*GCNP_SHH_UP_EARLY.V1_UP (170) MUT 0.0875 0.914 0.958 1 0.281 1
ESC_J1_UP_EARLY.V1_DN (156) MUT 0.0899 0.914 1 0.734 1 1
ERB2_UP.V1_UP (170) MUT 0.103 0.914 1 0.56 1 1
KRAS.300_UP.V1_UP (155) WT 0.108 0.914 1 0.994 1 1
BRCA1_DN.V1_UP (64) WT 0.125 0.914 1 1 1 1
AKT_UP.V1_UP (87) MUT 0.127 0.914 1 0.821 1 1
ERB2_UP.V1_DN (90) MUT 0.13 0.914 0.444 0.56 1 1
STK33_SKM_DN (97) MUT 0.139 0.914 1 0.56 1 1
ALK_DN.V1_UP (100) WT 0.146 0.914 1 1 1 1
Results for the MSigDB C6 v5.0 collection and p53 [4] gene expression data (188 total gene sets after size-based filtering). Significant q-values are marked in bold with a
*before the gene set name
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of this method for screening-testing [19] in the SGSF
approach [24]. Although the SGSE method was shown
to be superior to existing unsupervised techniques and
was able to significantly improve gene set testing power
when used in the SGSF screening-testing approach, the
method only supports testing against a competitive null
hypothesis and is not able to effectively identify biolog-
ically relevant gene sets for a number of important use
cases. To remedy the limitations of the SGSE method
and other available unsupervised techniques, we devel-
oped two new unsupervised gene set tests, the Marc˘enko-
Pastur Distribution Test (MPDT) and the Tracy-Widom
Test (TWT). Both the MPDT and the TWT support self-
contained and competitive null hypotheses and both are
based on random matrix theory (RMT) findings regard-
ing the distribution of the eigenvalues of matrices with a
whiteWishart distribution [32, 33]. As outlined in Section
“Random matrix theory (RMT) benefits”, the RMT
basis of both methods conveys several general benefits:
improved performance on high-dimensional data, robust-
ness to departures from normality and superior perfor-
mance on small sample sizes.
Table 1 lists a set of biologically relevant population
covariance matrix structures that illustrate the relative
benefits of the proposed MDPT and TWT methods and
existing methods such as SGSE and MLRT. These struc-
tures also formed the basis for the type I error con-
trol and power simulation designs detailed in Sections
“Simulation design to assess type I error control”
and “Simulation design to assess statistical power”. As
shown in the type I error control results in Section
“Type I error control results” and Table 4, all methods
had excellent type I error control on each of the evalu-
ated models. In contrast, the empirical power realized by
each of four methods, as illustrated in Table 5, diverged
significantly across each of the simulated models with
each method delivering the best power for at least one
model. Overall, the TWT method had the best perfor-
mance, with the top power for six of the 10 cases and close
to the best power for the remaining four cases. Sections
“Unsupervised gene set testing for the single block
model” through “Performance on gene expression data
and MSigDB collections” below provide a more detailed
discussion of these models and the simulation and real
data analysis results.
Unsupervised gene set testing for the single block model
For the single block model, represented by power
simulation models MVN-1 thru MVN-6 detailed in
Section “Simulation design to assess statistical power”, all
members of the gene set have a positive pairwise cor-
relation with almost no correlation with genes not in
the set. Such a covariance structure is quite common
for genomic data, e.g., microarray gene expression, and
gene sets containing co-regulated genes [11] or gene sets
based on the result of gene clustering [25]. For each of
the first four simulations models (MVN-1 thru MVN-
4), such a single block covariance structure was used in
which all variances were set to 1 and all covariances were
set to 0 except for the covariances between true gene
set members, which were set to an equal and positive
value. For these four models, the best power was gen-
erated by either the TWT method or the SGSE method
with the classicMLRTmethod performing well on the two
larger sample size models (MVN-1 and MVN-4) and the
MPDT method generating average power substantially
below the other methods. It is known that such a block
covariance matrix structure will tend to produce a first
principal component (PC) for the entire data set whose
associated eigenvector has large weights of the same sign
for all block members [39]. Because the SGSE method
is based on the association between gene set members
and the PCs of the entire data set, with weights based on
the associated eigenvalue significance, it is able to per-
form well when the first PC effectively captures the true
gene set signal. When the sample covariance matrix is
computed using just the gene set members for the single
block model, the first principal component can likewise
be expected to have large weights of the same sign for all
gene set members and a correspondingly large eigenvalue.
Importantly, the largest eigenvalue of the sample covari-
ance matrix for just the gene set members in this case can
be expected to be stochastically larger than the principal
eigenvalue of a sample covariance matrix for a random
group of genes of the same size since, for the single block
model, all covariances not between true gene set mem-
bers are 0. This expected difference between the largest
eigenvalues of random and non-random partitioned sam-
ple covariance matrices enabled the competitive TWT
method to also perform well for the single block use case.
The moderately higher average power achieved by the
SGSE method relative the TWTmethod for lower sample
sizes (MVN-2 and MVN3) may be due to the fact that the
SGSE method is parametric whereas the TWT method is
based on a permutation distribution. The fact that only
the largest eigenvalue will likely represent the non-null
gene set explains the poor performance of the MPDT
method, which is based on the bulk eigenvalue distribu-
tion. The satisfactory performance of the MLRT method
for the single block models was likely due to the fact that
the MVN distribution of the simulated data aligned with
the distributional assumptions of the MLRT test.
For single block models MVN-5 and MVN-6, the best
power was provided by either the TWT method or
the MPDT method. The covariance structure used for
these simulations specified an elevated variance for true
gene set members with all covariances set to 0. Such a
covariance structure will tend to generate one PC for each
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variable that has an elevated variance with the loading
for that variable dominating the other loadings and the
eigenvalue associated with the PC similar in magnitude to
the variance of the variable. The signal for the true gene
set for these models was therefore spread across multiple
eigenvalues of the sample covariance matrix. Because the
MPDT method is based on all of eigenvalues of the parti-
tioned sample covariance matrix, its good relative power
was therefore expected for these models. Since no sin-
gle PC was closely associated with the true gene set, the
poor performance of the SGSEmethod was also expected.
Because the TWTmethod is based on just the magnitude
of the largest eigenvalue of the partitioned sample covari-
ance matrix, it was able perform well even though the
associated PC tended to represent just one gene set mem-
ber. The poor power of the MLRT method in these cases
was likely due to the fact that all population covariances
were 0.
Unsupervised gene set testing for the multi-block model
A multi-block covariance structure was used for model
MVN-7 in which the portion of the population covariance
matrix associated with the true gene set was divided into
5 disjoint 2 × 2 blocks with covariance 0.2. Multi-block
covariance structures are also quite common for genomic
data and biologically-based gene sets, especially large gene
sets that represent processes withmultiple modes of activ-
ity. Similar to the single block case, such a multi-block
structure will tend to produce one PC per block [39] and
will therefore distribute the signal for the true gene set
across multiple eigenvalues/PCs of the sample covariance
matrix. For MVN-7, the MLRTmethod had the best aver-
age power with the TWT and MPDT methods providing
comparable performance and the SGSE method returning
the worst average power. As detailed for models MVN-5
and MVN-6 above, the fact that multiple eigenvalues rep-
resent the true gene set is consistent with the good relative
power of the MPDT and TWTmethods and poor relative
power of the SGSE method. The superior relative perfor-
mance of the MLRTmethod for MVN-7, and the fact that
the MLRT method generated much larger average power
forMVN-7 than forMVN-5 orMVN-6, is likely due to the
presence of non-zero population covariance values in the
MVN-7 model.
The anti-correlated multi-block covariance structure
used for MVN-8 was a variation of the multi-block model
used for MVN-7. In this case, the portion of the covari-
ance matrix associated with the true gene set was split
into two blocks with correlations between members of
the same block set to 0.1. The key difference between
the multi-block structure and the anti-correlated multi-
block structure used for MVN-8 is that the covariance
between members of different blocks was set to -0.1
rather than 0. This type of structure also corresponds to
a biologically realistic class of gene sets, e.g., a metabolic
pathway that has several distinct modes of action rep-
resented by different subsets of associated genes. The
covariance structure in MVN-8 leads to two PCs repre-
senting the variable group members with opposite sign
loadings for the members of each block. For MVN-8, the
TWT method provided the best power with the MLRT
method a close second and significantly lower power for
theMPDT and SGSEmethods. The opposite sign loadings
pose a particular problem for the SGSE method which
effectively compares the mean PC loading for members
of the gene set against the mean PC loading for non-gene
set members. The TWT method, on the other hand, is
based just on the magnitude of the largest eigenvalue so
has power comparable to the single block models. The
results for the MPDT and MLRT methods on MVN-8
are explained by reasoning similar to that outlined for the
single block models above.
Unsupervised gene set testing for the repeated block
model
Similar to the single block and multi-block models, the
repeated block model, represented by MVN-8, will tend
to produce one PC per each block that has large and equal
signed loadings for all block members. Such a model can
be expected when there are multiple independent gene
sets associated with a specific data set. Although every
gene set in this case has a population covariance matrix
with equal and non-zero covariance values, the gene sets
are significant relative to H0 (8) in the main manuscript
since a random partition of the sample covariance matrix
of the same size as the gene sets will tend to include
zero covariance values as well due to the zero covariance
between members of different gene sets For model MVN-
9, the TWT method had substantially higher power than
all other methods. In this case, the population covariance
matrix was divided into one block per disjoint gene set.
For the SGSE method, the poor power is explained by the
fact that each gene set will only be associated with one
PC yet multiple PCs will have significant eigenvalues so,
when the association measures are combined for all PCs,
the gene set will not appear enriched relative to a com-
petitive null hypothesis. The poor power of the MPDT
and MLRT methods relative to the TWT method is likely
due to the fact that MPDT and MLRT consider all of the
eigenvalues of the partitioned sample covariance matrix
whereas the TWT method is based on just the largest
eigenvalue.
Unsupervised gene set testing for non-normal data
For many types of genomic data, such as the geno-
typic data collected by genome-wide association stud-
ies, the measured values of genomic variables are not
normally distributed. For the case of single nucleotide
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polymorphisms (SNPs) specified using additive coding,
a data model similar to Binom-1 can be expected. For
this model, the TWT method had the best average power
followed closely by the SGSE method. The superior per-
formance of the TWT and SGSE methods relative to
the MPDT and MLRT methods follows from the uni-
versality properties of the Tracy-Widom distribution, i.e.,
the Tracy-Widom distribution of the scaled and centered
largest eigenvalue is known to be robust to departures
from normality for x [38].
Performance on gene expression data andMSigDB
collections
To assess the practical utility of the TWT and the
MPDT methods, a wFDR analysis (detailed in Section
“Real data analysis design”) was performed on two real
gene expression data sets relative to MSigDB gene set col-
lections. As detailed in Section “Real data results” above
and the Additional file 1, the results on the p53 and
leukemia data sets mirrored the results on the simula-
tion examples. Specifically, the relative ranking of the four
methods varied considerably across the MSigDB collec-
tions and two data sets with the TWT and SGSE meth-
ods delivering the best overall performance. As seen in
Table 6, the eight most significantly enriched C7 gene sets
relative to AML vs. ALL status represent the differential
expression of different types of white blood cells (primar-
ily lymphoid vs. myeloid cells) and are therefore biologi-
cally consistent with the phenotype. Although these gene
sets have enrichment p-values that are significant prior to
MHC, after controlling the FDR for the family of all 1910
analyzed C7 gene sets, none have significant q-values.
When a wFDR approach is taken using weights based on
the p-values from the TWT test, three of the top eight
gene sets had significant q-values (these are marked in
bold in Table 6 with a * prefixing the gene set name).When
weights were based on either the MLRT, SGSE or MPDT
method, no significant q-values were generated.
For the p53 gene expression data and C6 collection,
the impact of weighting was less pronounced. As seen
in Table 7, the two most significantly enriched C6 gene
sets relative to p53 mutated status represent either up-
regulated or down-regulated genes in the NCI-60 panel of
cell lines with mutated p53. In this case, both gene sets
had significant q-values without any weighting and when
p-values were weighted using any of the unsupervised
gene set tests. However, the use of the TWT and MPDT
methods to generate weights also produced marginally
significant q-values of less than 0.3 for several other bio-
logically plausible gene sets for the p53 data. Similar to the
leukemia results, these q-values are marked in bold with *
prefixing the gene set names.
Tables S1 and S14 in the Additional file 1 show the
overall association between the supervised gene set test
p-values generated by the CAMERA method and either
the mean inter-gene correlation among gene set mem-
bers (as estimated by CAMERA) or the unsupervised
p-values generated by the MLRT, SGSE, TWT andMPDT
methods. These tables demonstrate the general associa-
tion between the departure of gene set members from
an identity covariance structure and biological activity
as represented by the supervised gene set p-values. As
seen in these tables, the p-values generated by the TWT
and SGSE methods have the largest correlation with the
supervised p-values for both data sets across the different
MSigDB gene set collections. In contrast, the mean inter-
gene correlation estimated by the CAMERA method,
while still associated with the supervised p-values, is
a comparatively poor predictor of gene set biological
activity.
Conclusions
The TWT and MPDT methods represent important
methodological advances for unsupervised gene set test-
ing. These new methods support both self-contained and
competitive null hypotheses and provide performance
superior to existing approaches, such as the SGSE and
MLRT methods, on a set of biologically important data
structures. The TWTmethod provides good power across
most expected models and is clearly the best choice for
non-normal data (e.g., model Binom-1), an anti-correlated
multi-block structure (e.g., model MVN-7) or a repeated
block structure (e.g., model MVN-8). If a single block
structure can be expected with standardized variance (i.e.,
all members of the gene set have a positive pairwise cor-
relation with almost no correlation with genes not in the
set and variance of 1) and the number of samples is small
relative to the size of the gene set (i.e., n/p ≤ 5), as rep-
resented by models MVN-2 and MVN-3, then the SGSE
method is the best choice. If variance of each gene in the
set is large relative to genes not in the set (as represented
by model MVN-6), then the MPDT method can provide
the best results. For multi-block data (e.g., model MVN-
7) or data following a single block structure with a large
correlation between gene set members (e.g., MVN-4), the
best results are generated by the classic MLRT method.
Important directions for future research include the
assessment of a broader range of biologically relevant
covariance structures, the exploration of other classes of
non-normal data, and the use of the TWT and MPDT
methods to make novel biological findings via p-value
weighting.
Additional file
Additional file 1: Supplementary results for leukemia and p53 gene
expression examples. (168 KB PDF)
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